Trials / Active Not Recruiting
Active Not RecruitingNCT06356597
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Division of Gastroenterology and Hepatology,Renji Hospital, School of Medicine, Shanghai Jiao Tong University
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Jing-yuan Fang, MD, Ph. D · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the efficacy and safety of Tislelizumab with Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with high abundance of Fusobacterium nucleatum in a single arm Phase II clinical.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab with Fruquintinib, Metronidazole | Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day. Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle. |
Timeline
- Start date
- 2024-04-19
- Primary completion
- 2026-12-30
- Completion
- 2027-12-12
- First posted
- 2024-04-10
- Last updated
- 2026-02-24
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06356597. Inclusion in this directory is not an endorsement.